Chronic Myeloid Leukemia, BCR-ABL1+
Therapeutic response
Precision oncology relationships for therapeutic response involving this cancer type.
| Organization(s) | Biomarker(s) | Cancer type | Therapy(ies) | |
|---|---|---|---|---|
| FDA (3) | BCR::ABL1 | Chronic Myeloid Leukemia, BCR-ABL1+ | Dasatinib | |
| EMA (2) FDA (2) | BCR::ABL1 | Chronic Myeloid Leukemia, BCR-ABL1+ | Imatinib | |
| FDA (3) | BCR::ABL1 | Chronic Myeloid Leukemia, BCR-ABL1+ | Nilotinib | |
| FDA (2) | BCR::ABL1 | Chronic Myeloid Leukemia, BCR-ABL1+ | Asciminib | |
| EMA (3) | CD22 + | Chronic Myeloid Leukemia, BCR-ABL1+ | Bosutinib |